----item----
version: 1
id: {67DE35C3-B37E-48BF-B576-76A7347520A0}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/08/30/PharmAsia News Business Bulletin
parent: {E1B0B0CF-0464-4BAC-AFD7-135546113D2D}
name: PharmAsia News Business Bulletin
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: e7ca9078-19df-41b0-bf61-d2ed2d8b840a

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 32

PharmAsia News Business Bulletin
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 32

PharmAsia News Business Bulletin
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 6081

<p>A new regular roundup of commercial stories appearing in <i>Scrip</i>&rsquo;s sister publication <i>PharmAsia News</i>, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace.</p><p>Full stories can be accessed by clicking on the story title (subscription required).</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/9/3/incyte-hengrui-in-biggest-ever-china-pharma-outlicensing-deal" target="_new">Incyte, Hengrui In 'Biggest Ever ' China Pharma Out-Licensing Deal</a></p><p>Incyte has acquired most global rights to an immuno-oncology antibody developed by China's Jiangsu Hengrui, in a deal worth up to nearly $800m plus royalties that will give the US firm a foothold in the PD-1 area and open up new combination therapies.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/9/1/a-hard-look-how-did-china-pharma-growth-fall-so-fast-so-steeply" target="_new">A Hard Look: How Did China Pharma Growth Fall So Fast, So Steeply?</a></p><p>While many are still shocked by the double-digit drop in quarterly pharma sales in the world's second-largest economy, the underlying factors for the fast deterioration in China have in fact been brewing for some time and are multi-faceted, Yang Dongsheng of the R&D based Pharmaceutical Association Committee (RDPAC) tells PharmAsia News in an exclusive interview.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/8/28/wuxi-pharmatech-pushing-ahead-with-$3bn-goprivate-deal" target="_new">Wuxi PharmaTech Pushing Ahead with $3bn Go-Private Deal</a></p><p>The continuous development of Wuxi PharmaTech needs ongoing financial support, and while US listing has been an important source for funding, the major Chinese provider of contract development services to the global pharma industry is now looking to go private in a move that aims to take advantage of favorable investor sentiment and bring value to shareholders.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/8/20/az-merck-sanofi-the-winners-in-drastic-china-slowdown" target="_new">AZ, Merck, Sanofi The Winners In Drastic China Slowdown</a></p><p>A drastic slowdown in China has impacted pharma multinationals, with average growth dipping by double digits in the last quarter. PharmAsia News has combed through earnings reports to bring you the winners, laggards and the most successful strategies.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/9/3/daiichi-sankyo-builds-vaccines-business-via-flumist-deal" target="_new">Daiichi Sankyo Builds Vaccines Business Via FluMist Deal</a></p><p>Daiichi Sankyo is adding to its vaccines portfolio in Japan through a deal to market in the country AstraZeneca's nasally administered quadrivalent flu product FluMist.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/9/3/strategic-decision-prompts-janssen-exit-from-chimed-deal" target="_new"> 'Strategic Decision' Prompts Janssen Exit From Chi-Med Deal</a></p><p>One of the largest collaborative deals in China's pharmaceutical industry has fallen apart, as Janssen has opted to terminate an R&D alliance agreement in the inflammation/immunology area with Hutchison China MediTech, although the two firms intend to continue to work together in other areas.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/9/2/pharmula-acquisition-to-provide-us-expansion-base-for-jingxin" target="_new">Pharmula Acquisition To Provide US Expansion Base For Jingxin</a></p><p>Shanghai-listed Jingxin Pharmaceutical is aiming to tap into the US market for its growing formulations business through the majority acquisition of Pharmula, a US-based contract services firm. The Chinese manufacturer is looking to capitalize on its partners' strength in R&D to facilitate its global expansion.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/8/27/china-generic-sildenafil-market-growing-but-challenges-ahead" target="_new">China Generic Sildenafil Market Growing But Challenges Ahead</a></p><p>The first Chinese generic version of Viagra has racked up healthy sales since its launch and more domestic pharmaceutical companies are now readying themselves to capture the opportunity in the erectile dysfunction market with cheaper homegrown generics since Pfizer lost its Chinese patent for sildenafil last year.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/8/30/korea-toujeo-ok-sets-stage-for-tresiba-clash" target="_new">Korea Toujeo OK Sets Stage for Tresiba Clash</a></p><p>Sanofi's next-generation basal insulin Toujeo has been approved in South Korea and looks set to compete with Novo Nordisk's Tresiba, which is also expected to be launched there soon.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/8/27/korean-foreign-pharms-call-for-reasonable-drug-price-system" target="_new">Korean, Foreign Pharms Call For 'Reasonable' Drug Price System</a></p><p>South Korean and foreign pharma firms have jointly urged the Korean government to postpone a planned drug price cut by one year in an effort to overcome the impact of the MERS outbreak, and have promised to cooperate to propose a balanced new drug pricing system as well as to recommend steps to promote better R&D in the sector.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/8/20/gskdesano-tieup-bring-large-dolutegravir-price-cuts" target="_new">GSK/Desano Tie-Up To Bring Large Dolutegravir Price Cuts</a></p><p>HIV drug Tivicay is expected to become cheaper in China under a recent manufacturing deal between ViiV and Desano. The Chinese firm expects to gain a 35% share of the global generic antiretroviral API supply market this year after patent licensing agreements with the Medicines Patent Pool.</p><p><p><a href="http://www.pharmasianews.com" target="_new">www.pharmasianews.com</a></p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 249

<p>A new regular roundup of commercial stories appearing in <i>Scrip</i>&rsquo;s sister publication <i>PharmAsia News</i>, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 32

PharmAsia News Business Bulletin
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150830T082419
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150830T082419
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150830T082419
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC029685
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 32

PharmAsia News Business Bulletin
----field----
field: {53288D3D-66D7-4ACE-B3E4-D7D02B1F3672}
name: Referenced Companies
key: referenced companies
content-length: 9

198800586
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{DB39CCA6-EB88-422C-8247-AB4AD01491E2}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 13

Headline News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

360171
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042445Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

e7ca9078-19df-41b0-bf61-d2ed2d8b840a
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042445Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
